Soleno Therapeutics (SLNO) Stock Price, News & Analysis

Company Overview

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Key Stats

• Today's Range: $77.73 to $83.42
• 50-Day Range: $73.24 to $88.49
• 52-Week Range: $41.50 to $90.32
• Volume: 1.78 million shs
• Average Volume: 1.45 million shs
• Market Capitalization: $3.97 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $113.30
• Consensus Rating: Buy

Soleno Therapeutics Stock Analysis - MarketRank™

Soleno Therapeutics scored higher than 91% of companies evaluated by MarketBeat, and ranked 149th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Soleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Soleno Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Soleno Therapeutics are expected to grow in the coming year, from ($3.72) to ($2.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Soleno Therapeutics is -19.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Soleno Therapeutics is -19.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Soleno Therapeutics has a P/B Ratio of 13.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.40% of the float of Soleno Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Soleno Therapeutics has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Soleno Therapeutics has recently increased by 9.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Soleno Therapeutics does not currently pay a dividend.

Dividend Growth

Soleno Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.55

Percentage of Shares Shorted

13.40% of the float of Soleno Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Soleno Therapeutics has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Soleno Therapeutics has recently increased by 9.72%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.96

News Sentiment

Soleno Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Soleno Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 5 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

MarketBeat Follows

3 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $339,381.00 in company stock.

Percentage Held by Insiders

Only 6.40% of the stock of Soleno Therapeutics is held by insiders.

Percentage Held by Institutions

97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SLNO Stock Analysis - Frequently Asked Questions

How have SLNO shares performed this year?

Soleno Therapeutics' stock was trading at $44.95 on January 1st, 2025. Since then, SLNO stock has increased by 75.1% and is now trading at $78.71.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.44. The business earned $32.66 million during the quarter, compared to the consensus estimate of $3.91 million.
Read the conference call transcript.

When did Soleno Therapeutics' stock split?

Soleno Therapeutics's stock reverse split before market open on Friday, August 26th 2022.The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Soleno Therapeutics' major shareholders?

Top institutional investors of Soleno Therapeutics include Emerald Advisers LLC (1.34%), Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. (1.00%), Bank of New York Mellon Corp (0.96%) and Emerald Mutual Fund Advisers Trust (0.81%). Insiders that own company stock include Vivo Opportunity, Llc, Perceptive Advisors Llc, Bhatnagar Anish, Jack W Schuler, James H Mackaness, Kristen Yen, Michael F Huang, Patricia C Hirano and Matthew Pauls.
View institutional ownership trends.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), Disc Medicine (IRON), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SLNO
• CIK: 1484565
• Web: www.soleno.life
• Phone: (650) 213-8444
• Fax: 650-213-8383
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Soleno Therapeutics: $113.30
• High Price Target: $145.00
• Low Price Target: $100.00
• Potential Upside/Downside: +43.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.09
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$175.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.21%
• Return on Assets: -57.44%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 19.64
• Quick Ratio: 19.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.68 per share
• Price / Book: 13.86

Miscellaneous

• Outstanding Shares: 50,390,000
• Free Float: 47,169,000
• Market Cap: $3.97 billion
• Optionable: Optionable
• Beta: -2.56